3,4-methylenedioxyamphetamine has been researched along with Substance-Related Disorders in 147 studies
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.
Substance-Related Disorders: Disorders related to substance use or abuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent data show a connection between substance abuse and other behaviors considered normal, such as passionate love." | 2.49 | Preventing toxicomania and addictive behaviour in adolescence. ( Manceaux, P; Maricq, A; Reynaert, C; Zdanowicz, N, 2013) |
| "Here, we review research on drug addiction in parallel with research on social attachments, including parent-offspring attachments and social bonds between mating partners." | 2.48 | The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. ( Burkett, JP; Young, LJ, 2012) |
| " MDMA was either equally toxic or slightly to moderately less toxic than its close congener, MDA, (+/-)-3,4-methylenedioxyamphetamine." | 2.37 | Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. ( Davis, WM; Hatoum, HT; Waters, IW, 1987) |
| "All cases of drug abuse identified by hair analysis were from the public security organs in Shanghai, China." | 1.56 | A Retrospective of Prevalence of Drugs of Abuse by Hair Analysis in Shanghai using LC-MS-MS. ( Cui, J; Liu, W; Shen, B; Shen, M; Wang, X; Xiang, P; Zhang, S; Zhuo, Y, 2020) |
| "Despite attention paid to substance use during pregnancy, understandings of young Aboriginal women's experiences based on their perspectives have been virtually absent in the published literature." | 1.46 | Understanding the Life Histories of Pregnant-Involved Young Aboriginal Women With Substance Use Experiences in Three Canadian Cities. ( Bottorff, JL; Kurtz, DL; Oelke, ND; Shahram, SZ; Spittal, PM; Thomas, V, 2017) |
| "Drug addiction is a serious health problem." | 1.42 | The core of love when caring for patients suffering from addiction. ( Eriksson, K; Råholm, MB; Thorkildsen, KM, 2015) |
| " However, such dosing regimens do not adequately mimic the intermittent use patterns commonly seen in adolescent recreational ecstasy users." | 1.35 | Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. ( Meyer, JS; Piper, BJ; Vancollie, VE, 2008) |
| "Dating, sexual, and substance use activities may figure importantly in the way that adolescents experience their age." | 1.34 | Dating, sex, and substance use as correlates of adolescents' subjective experience of age. ( Arbeau, KJ; Galambos, NL; Mikael Jansson, S, 2007) |
| "XTC and other amphetamines are considered to be safe by the majority of partying young people who are unaware of (or unwilling to know about) the acute and chronic toxicity of these substances, and these drugs are widespread, illicit stimulants." | 1.33 | Amphetamine toxicity in the emergency department. ( Bronselaer, K; De Feyter, K; De Munnynck, K; Sabbe, M; Smets, G; Van de Voorde, W, 2005) |
| "This drug abuse is rarely reported spontaneously." | 1.29 | [Epileptic insults, cerebral infarction and rhabdomyolysis as complications of amphetamine use]. ( Korten, JJ; Roebroek, RM, 1996) |
| " Side effects, insight gained, pleasure, and intensity of the MDMA experience were evaluated as were the influence of set and setting at the time the MDMA was taken and the dosage utilized." | 1.28 | Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. ( Bravo, GL; Grob, CS; Liester, MB; Walsh, RN, 1992) |
| "The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as "ecstasy", is now widely known in both the USA and UK, but the patterns of illness remain varied." | 1.28 | Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") ( Dawling, S; Henry, JA; Jeffreys, KJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (23.13) | 18.7374 |
| 1990's | 72 (48.98) | 18.2507 |
| 2000's | 17 (11.56) | 29.6817 |
| 2010's | 18 (12.24) | 24.3611 |
| 2020's | 6 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, GF | 1 |
| Lee, WM | 1 |
| Li, CK | 1 |
| Burgueño, MJ | 1 |
| Sánchez, S | 1 |
| Castro, MÁ | 1 |
| Mateos-Campos, R | 1 |
| Wang, X | 1 |
| Cui, J | 1 |
| Zhuo, Y | 1 |
| Shen, B | 1 |
| Zhang, S | 1 |
| Liu, W | 1 |
| Shen, M | 1 |
| Xiang, P | 1 |
| Bade, R | 1 |
| White, JM | 1 |
| Nguyen, L | 1 |
| Pandopulos, AJ | 1 |
| Gerber, C | 1 |
| Heran, MKS | 1 |
| Nugent, JP | 1 |
| Fatehi, M | 1 |
| Haw, CS | 1 |
| Ronan, GP | 1 |
| Ronan, N | 1 |
| McGettigan, S | 1 |
| Browne, G | 1 |
| Meyer, JS | 1 |
| Piper, BJ | 1 |
| Vancollie, VE | 1 |
| Black, DL | 1 |
| Cawthon, B | 1 |
| Robert, T | 1 |
| Moser, F | 1 |
| Caplan, YH | 1 |
| Cone, EJ | 1 |
| Drees, JC | 1 |
| Stone, JA | 1 |
| Wu, AH | 1 |
| Herbert, J | 1 |
| Tracey, JA | 1 |
| Kasprzyk-Hordern, B | 1 |
| Baker, DR | 1 |
| Cole, JC | 1 |
| Sumnall, HR | 1 |
| Marchioro, L | 1 |
| Bassetto, F | 1 |
| Dall'Olio, G | 1 |
| Tedeschi, L | 2 |
| Castagna, F | 2 |
| Plebani, M | 1 |
| Smets, G | 1 |
| Bronselaer, K | 1 |
| De Munnynck, K | 1 |
| De Feyter, K | 1 |
| Van de Voorde, W | 1 |
| Sabbe, M | 1 |
| Liu, RH | 1 |
| Liu, HC | 1 |
| Lin, DL | 1 |
| Kłys, M | 1 |
| Rojek, S | 1 |
| Woźniak, K | 1 |
| Rzepecka-Woźniak, E | 1 |
| Cohen, S | 2 |
| Frank, RS | 1 |
| Mack, RB | 2 |
| Kintz, P | 1 |
| Cirimele, V | 1 |
| Tracqui, A | 1 |
| Mangin, P | 1 |
| Renton, RJ | 1 |
| Cowie, JS | 1 |
| Oon, MC | 1 |
| Allen, RP | 1 |
| McCann, UD | 3 |
| Ricaurte, GA | 7 |
| Watson, JD | 1 |
| Ferguson, C | 1 |
| Hinds, CJ | 1 |
| Skinner, R | 1 |
| Coakley, JH | 1 |
| Manchanda, S | 1 |
| Connolly, MJ | 1 |
| Forrest, AR | 3 |
| Galloway, JH | 1 |
| Marsh, ID | 1 |
| Strachan, GA | 1 |
| Clark, JC | 2 |
| Kramer, K | 1 |
| Azmitia, EC | 1 |
| Whitaker-Azmitia, PM | 1 |
| Cuomo, MJ | 1 |
| Dyment, PG | 1 |
| Gammino, VM | 1 |
| Gouzoulis, E | 1 |
| Borchardt, D | 1 |
| Hermle, L | 2 |
| Frison, G | 1 |
| Giorgetti, R | 1 |
| Ferrara, SD | 1 |
| Levine, AJ | 1 |
| Drew, S | 1 |
| Rees, GM | 1 |
| Barrett, PJ | 1 |
| Taylor, GT | 1 |
| Cadier, MA | 1 |
| Clarke, JA | 1 |
| Schwartz, RH | 1 |
| Cox, DE | 1 |
| Tehan, B | 1 |
| Hardern, R | 1 |
| Bodenham, A | 1 |
| Roebroek, RM | 1 |
| Korten, JJ | 1 |
| Drake, WM | 1 |
| Broadhurst, PA | 1 |
| Milroy, CM | 2 |
| Brown, ER | 1 |
| Jarvie, DR | 1 |
| Simpson, D | 1 |
| Shewan, D | 1 |
| Dalgarno, P | 1 |
| Stell, JM | 1 |
| Ryan, JM | 1 |
| Kronstrand, R | 1 |
| Fidler, H | 1 |
| Dhillon, A | 1 |
| Gertner, D | 1 |
| Burroughs, A | 1 |
| Rezvani, K | 1 |
| Kurbaan, AS | 1 |
| Brenton, D | 1 |
| Sultana, SR | 1 |
| Byrne, DJ | 1 |
| Gouzoulis-Mayfrank, E | 1 |
| Kovar, KA | 1 |
| Sass, H | 1 |
| Kikura, R | 1 |
| Nakahara, Y | 1 |
| Mieczkowski, T | 1 |
| Tagliaro, F | 1 |
| de la Fuente de Hoz, L | 1 |
| Rodríguez Arenas, MA | 1 |
| Vicente Orta, J | 1 |
| Sánchez Payá, J | 1 |
| Barrio Anta, G | 1 |
| Murthy, BV | 1 |
| Roberts, NB | 1 |
| Wilkes, RG | 1 |
| Mørland, J | 1 |
| Ho, BK | 1 |
| Bogusz, MJ | 1 |
| Keller, T | 1 |
| Miki, A | 1 |
| Regenscheit, P | 1 |
| Dirnhofer, R | 1 |
| Schneider, A | 1 |
| Tsuchihashi, H | 1 |
| de Visme, PG | 1 |
| Felgenhauer, N | 1 |
| Zilker, T | 1 |
| Allen, DL | 1 |
| Oliver, JS | 1 |
| Carter, N | 1 |
| Rutty, GN | 1 |
| Rome, ES | 1 |
| Lukaszewski, T | 1 |
| Griffiths, RR | 1 |
| Winger, G | 1 |
| Brady, JV | 1 |
| Snell, JD | 1 |
| Kaskey, GB | 1 |
| McGuire, P | 2 |
| Fahy, T | 2 |
| Campkin, NT | 1 |
| Davies, UM | 1 |
| Liester, MB | 2 |
| Grob, CS | 2 |
| Bravo, GL | 2 |
| Walsh, RN | 2 |
| Woods, JD | 1 |
| Henry, JA | 3 |
| Fahal, IH | 1 |
| Sallomi, DF | 1 |
| Yaqoob, M | 1 |
| Bell, GM | 1 |
| Jeffreys, KJ | 1 |
| Dawling, S | 1 |
| Solowij, N | 1 |
| Hall, W | 1 |
| Lee, N | 1 |
| Singarajah, C | 1 |
| Lavies, NG | 1 |
| Rittoo, DB | 2 |
| Rittoo, D | 3 |
| Ellis, SJ | 1 |
| Larner, AJ | 1 |
| Gorard, DA | 1 |
| Davies, SE | 1 |
| Clark, ML | 1 |
| Shearman, JD | 1 |
| Chapman, RW | 1 |
| Satsangi, J | 1 |
| Ryley, NG | 1 |
| Weatherhead, S | 1 |
| De Silva, RN | 1 |
| Harries, DP | 1 |
| Sawyer, J | 1 |
| Stephens, WP | 1 |
| Lyttle, T | 1 |
| Montagne, M | 1 |
| Krystal, JH | 3 |
| Price, LH | 3 |
| Opsahl, C | 1 |
| Heninger, GR | 3 |
| Appel, JB | 1 |
| Baker, LE | 1 |
| Barrett, RL | 1 |
| Broadbent, J | 1 |
| Michael, EM | 1 |
| Riddle, EE | 1 |
| Van Groll, BJ | 1 |
| Prat, A | 1 |
| Montero, M | 1 |
| Reig, R | 1 |
| Sanz, P | 1 |
| Winstock, AR | 1 |
| Chadwick, IS | 1 |
| Curry, PD | 1 |
| Linsley, A | 1 |
| Freemont, AJ | 1 |
| Doran, B | 1 |
| Schifano, F | 1 |
| Kaminer, Y | 1 |
| Zemishlany, Z | 1 |
| Finnegan, KT | 1 |
| Irwin, I | 1 |
| Langston, JW | 1 |
| van Brussel, GH | 1 |
| Grob, C | 1 |
| Bravo, G | 1 |
| Walsh, R | 1 |
| Nichols, GR | 1 |
| Davis, GJ | 1 |
| Corrigan, CA | 1 |
| Ransdell, JS | 1 |
| Peroutka, SJ | 3 |
| Edwards, G | 1 |
| Laverty, R | 1 |
| Logan, BJ | 1 |
| Davis, WM | 1 |
| Hatoum, HT | 1 |
| Waters, IW | 1 |
| Frith, CH | 1 |
| Chang, LW | 1 |
| Lattin, DL | 1 |
| Walls, RC | 1 |
| Hamm, J | 1 |
| Doblin, R | 1 |
| Barnes, DM | 2 |
| Jacobson, AE | 1 |
| Newman, H | 1 |
| Harris, H | 1 |
| Woolverton, WL | 1 |
| Houston, AR | 1 |
| Snyder-Young, D | 1 |
| Perry, M | 1 |
| Flessen, M | 1 |
| Lincoln, AK | 1 |
| Taylor, KJ | 1 |
| Költő, A | 1 |
| Cosma, A | 1 |
| Young, H | 1 |
| Moreau, N | 1 |
| Pavlova, D | 1 |
| Tesler, R | 1 |
| Thorsteinsson, EB | 1 |
| Vieno, A | 1 |
| Saewyc, EM | 1 |
| Nic Gabhainn, S | 1 |
| Foglia, MB | 1 |
| Merrin, GJ | 1 |
| Ames, ME | 1 |
| Sturgess, C | 1 |
| Leadbeater, BJ | 1 |
| Kostick, KM | 1 |
| Schensul, JJ | 1 |
| Manceaux, P | 1 |
| Maricq, A | 1 |
| Zdanowicz, N | 1 |
| Reynaert, C | 1 |
| Thorkildsen, KM | 1 |
| Eriksson, K | 1 |
| Råholm, MB | 1 |
| Stauffer, CS | 1 |
| Woolley, JD | 1 |
| Lee, MY | 1 |
| Zaharlick, A | 1 |
| Akers, D | 1 |
| Shahram, SZ | 1 |
| Bottorff, JL | 1 |
| Kurtz, DL | 1 |
| Oelke, ND | 1 |
| Thomas, V | 1 |
| Spittal, PM | 1 |
| Marcellus, L | 1 |
| Reynaud, M | 2 |
| Karila, L | 1 |
| Blecha, L | 1 |
| Benyamina, A | 1 |
| Chen, AC | 1 |
| Thompson, EA | 1 |
| Morrison-Beedy, D | 1 |
| Sussman, S | 1 |
| Aubin, HJ | 1 |
| Leventhal, AM | 1 |
| Proudfoot, J | 1 |
| Whitton, A | 1 |
| Parker, G | 1 |
| Doran, J | 1 |
| Manicavasagar, V | 1 |
| Delmas, K | 1 |
| Burkett, JP | 1 |
| Young, LJ | 1 |
| Sprott, JC | 1 |
| McGee, EM | 1 |
| Arbeau, KJ | 1 |
| Galambos, NL | 1 |
| Mikael Jansson, S | 1 |
| Dunlap, E | 1 |
| Stürzenhofecker, G | 1 |
| Johnson, B | 1 |
| Florsheim, P | 1 |
| Moore, DR | 1 |
| Frosch, WA | 1 |
| Robbins, E | 1 |
| Robbins, L | 1 |
| Stern, M | 1 |
| Rickert, VI | 1 |
| Wiemann, CM | 1 |
| Muller, J | 1 |
| Davidson, V | 1 |
| Burdsal, C | 1 |
| Greenberg, G | 1 |
| Bell, M | 1 |
| Reynolds, S | 1 |
| Perais, V | 1 |
| Duval, F | 1 |
| Walsh, A | 1 |
| Beyer, JA | 1 |
| Streit, F | 1 |
| Halsted, DL | 1 |
| Pascale, PJ | 1 |
| Tec, L | 1 |
| Levine, SV | 1 |
| Carr, RP | 1 |
| Horenblas, W | 1 |
| McKenna-Hartung, S | 1 |
| Hartung, JR | 1 |
| Baxter, JC | 1 |
| Burke, EL | 1 |
| Huyghe, B | 1 |
| Ryle, A | 1 |
| Allen, JR | 1 |
| West, LJ | 1 |
| Edwards, AE | 1 |
| Bloom, MH | 1 |
| Hoppe, KD | 1 |
| Molnar, J | 1 |
| Newell, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 6-week Trial of Oxytocin for Co-occurring Cocaine and Opioid Use Disorders[NCT03016598] | Phase 2 | 42 participants (Actual) | Interventional | 2018-01-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Aim 6: To evaluate the effectiveness of intranasal oxytocin on reducing stress biomarkers in response to the TSST. (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | (ug/dL) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Initial Cortisol Levels (ug/dL) Week 1 | Pre-Trier Cortisol Levels (ug/dL) Week 1 | Immediately Post-Trier Cortisol Levels (ug/dL) Week 1 | 20Minutes Post-Trier Cortisol Levels (ug/dL) Week 1 | Initial Cortisol Levels (ug/dL) Week 7 | Pre-Trier Cortisol Levels (ug/dL) Week 7 | Immediately Post-Trier Cortisol Levels (ug/dL) Week 7 | 20 Minutes Post-Trier Cortisol Levels (ug/dL) Week 7 | |
| Oxytocin | 0.331 | 0.283 | 0.286 | 0.29 | 0.206 | 0.156 | 0.167 | 0.175 |
| Placebo | 0.319 | 0.193 | 0.242 | 0.211 | 0.259 | 0.197 | 0.184 | 0.168 |
Aim 6: To evaluate the effectiveness of intranasal oxytocin on reducing stress biomarkers in response to the TSST. (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | (pg/mL) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Initial DHEA Levels (pg/mL) Week 1 | Pre-Trier DHEA Levels (pg/mL) Week 1 | Immediately Post-Trier DHEA Levels (pg/mL) Week 1 | 20 Minutes Post-Trier DHEA Levels (pg/mL) Week 1 | Initial DHEA Levels(pg/mL) Week 7 | Pre-Trier DHEA Levels (pg/mL) Week 7 | Immediately Post-Trier DHEA Levels (pg/mL) Week 7 | 20 Minutes Post-Trier DHEA Levels (pg/mL) Week 7 | |
| Oxytocin | 86.230 | 90.313 | 100.468 | 81.742 | 87.674 | 75.221 | 84.230 | 82.009 |
| Placebo | 62.695 | 52.32 | 63.471 | 54.816 | 61.581 | 54.324 | 69.291 | 66.736 |
"Aim 3: To evaluate the effectiveness of intranasal oxytocin on reducing stress-related psycho-physiological measures in response to the Trier Social Stress Test (TSST).~The Trier Social Stress Test is a series of tasks which predictably induce stress in participants. First, physiological states are measured at baseline. Then participants are told they must prepare a 5 minute speech for a panel of researchers, which they then present. Participants are then asked verbal arithmetic questions. Finally, this is followed by a period of 5 minute rest referred to as the 'cooldown' period.~Heart rate was assessed at different time points during the TSST. These time point are as follows: baseline, during speech preparation, during speech presentation, during arithmetic problems, and during the cooldown period. Higher scores indicate higher stress levels." (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | Beats/minute (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Heart Rate Baseline: Week 1 | Heart Rate During Speech Prep: Week 1 | Heart Rate During Speech: Week 1 | Heart Rate During Arithmetic: Week 1 | Heart Rate Cooldown: Week 1 | Heart Rate Baseline: Week 7 | Heart Rate During Speech Prep: Week 7 | Heart Rate During Speech: Week 7 | Heart Rate During Arithmetic: Week 7 | Heart Rate Cooldown: Week 7 | |
| Oxytocin | 77.252 | 77.5306 | 85.3146 | 85.1227 | 72.0023 | 76.116 | 74.9320 | 81.8189 | 82.6265 | 74.9591 |
| Placebo | 68.1912 | 69.8634 | 79.4769 | 77.8194 | 68.8551 | 72.6821 | 69.9714 | 79.2512 | 82.8517 | 68.8543 |
Aim 5: To evaluate the effectiveness of intranasal oxytocin on improving psychosocial treatment engagement (social support) as measured by individual and group therapy attendance rates. (NCT03016598)
Timeframe: Visits 1-7, Up to 7 weeks
| Intervention | proportion of OTP visits attended (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Attendance Proportion: Week 1 | Attendance Proportion: Week 2 | Attendance Proportion: Week 3 | Attendance Proportion: Week 4 | Attendance Proportion: Week 5 | Attendance Proportion: Week 6 | Attendance Proportion: Week 7 | |
| Oxytocin | 0.9352 | 0.9333 | 0.9241 | 0.9260 | 0.8704 | 0.9444 | 1 |
| Placebo | 0.8406 | 0.8485 | 0.8429 | 0.7857 | 0.7476 | 0.7483 | 0.75 |
Aim 1: To evaluate the effectiveness of intranasal oxytocin on reducing stimulant use. (NCT03016598)
Timeframe: Baseline, Visits 1-7, up to 7 weeks
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stimulant Positive: Baseline | Stimulant Positive: Week 1 | Stimulant Postive: Week 2 | Stimulant Positive: Week 3 | Stimulant Positive: Week 4 | Stimulant Positive: Week 5 | Stimulant Positive: Week 6 | Stimulant Positive: Week 7 | |
| Oxytocin | 9 | 9 | 10 | 8 | 8 | 9 | 9 | 9 |
| Placebo | 12 | 10 | 11 | 11 | 12 | 12 | 11 | 11 |
"Aim 3: To evaluate the effectiveness of intranasal oxytocin on reducing stress-related psycho-physiological measures in response to the Trier Social Stress Test (TSST).~The Trier Social Stress Test is a series of tasks which predictably induce stress in participants. First, physiological states are measured at baseline. Then participants are told they must prepare a 5 minute speech for a panel of researchers, which they then present. Participants are then asked verbal arithmetic questions. Finally, this is followed by a period of 5 minute rest referred to as the 'cooldown' period.~Respiratory rate was assessed at different time points during the TSST. These time point are as follows: baseline, during speech preparation, during speech presentation, during arithmetic problems, and during the cooldown period. Higher scores indicate higher stress levels." (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | Breaths/minute (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory Rate Baseline: Week 1 | Respiratory Rate During Speech Prep: Week 1 | Respiratory Rate During Speech: Week 1 | Respiratory Rate During Arithmetic: Week 1 | Respiratory Rate Cooldown: Week 1 | Respiratory Rate Baseline: Week 7 | Respiratory Rate During Speech Prep: Week 7 | Respiratory Rate During Speech: Week 7 | Respiratory Rate During Arithmetic: Week 7 | Respiratory Rate Cooldown: Week 7 | |
| Oxytocin | 10.9117 | 11.0512 | 11.4533 | 10.56 | 10.6278 | 11.6779 | 10.6251 | 10.6675 | 10.4215 | 9.9913 |
| Placebo | 11.2000 | 12.292 | 12.3352 | 11.7565 | 10.5266 | 11.4583 | 12.7914 | 11.5526 | 12.4459 | 10.3816 |
"Aim 3: To evaluate the effectiveness of intranasal oxytocin on reducing stress-related psycho-physiological measures in response to the Trier Social Stress Test (TSST).~The Trier Social Stress Test is a series of tasks which predictably induce stress in participants. First, physiological states are measured at baseline. Then participants are told they must prepare a 5 minute speech for a panel of researchers, which they then present. Participants are then asked verbal arithmetic questions. Finally, this is followed by a period of 5 minute rest referred to as the 'cooldown' period.~Respiratory sinus arrythmia (RSA) was assessed at different time points during the TSST. These time point are as follows: baseline, during speech preparation, during speech presentation, during arithmetic problems, and during the cooldown period. Higher scores indicate higher stress levels." (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | milliseconds squared (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory Sinus Arrythmia During Baseline: Week 1 | Respiratory Sinus Arrythmia During Speech Prep: Week 1 | Respiratory Sinus Arrythmia During Speech: Week 1 | Respiratory Sinus Arrythmia During Arithmetic: Week 1 | Respiratory Sinus Arrythmia During Cooldown: Week1 | Respiratory Sinus Arrythmia During Baseline: Week 7 | Respiratory Sinus Arrythmia During Speech Prep: Week 7 | Respiratory Sinus Arrythmia During Speech: Week 7 | Respiratory Sinus Arrythmia During Arithmetic: Week 7 | Respiratory Sinus Arrythmia During Cooldown: Week 7 | |
| Oxytocin | 4.2435 | 4.6264 | 3.5542 | 3.5364 | 4.3466 | 4.1866 | 4.0099 | 3.6254 | 3.4825 | 3.9752 |
| Placebo | 4.9543 | 4.7393 | 3.8212 | 3.7893 | 4.4933 | 4.053 | 4.2972 | 3.5998 | 3.5267 | 4.1651 |
"Aim 3: To evaluate the effectiveness of intranasal oxytocin on reducing stress-related psycho-physiological measures in response to the Trier Social Stress Test (TSST).~The Trier Social Stress Test is a series of tasks which predictably induce stress in participants. First, physiological states are measured at baseline. Then participants are told they must prepare a 5 minute speech for a panel of researchers, which they then present. Participants are then asked verbal arithmetic questions. Finally, this is followed by a period of 5 minute rest referred to as the 'cooldown' period.~The root mean square of successive differences (RMSSD) were assessed at different time points during the TSST. These time point are as follows: baseline, during speech preparation, during speech presentation, during arithmetic problems, and during the cooldown period. Higher scores indicate higher stress levels. Calculated by measuring each successive time difference between heartbeats in ms." (NCT03016598)
Timeframe: Visits 1 and 7, up to 7 weeks
| Intervention | milliseconds (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| RMSSD During Baseline: Week 1 | RMSSD During Speech Prep: Week 1 | RMSSD During Speech: Week 1 | RMSSD During Arithmetic: Week 1 | RMSSD During Cooldown: Week 1 | RMSSD During Baseline Week 7 | RMSSD During Speech Prep: Week 7 | RMSSD During Speech: Week 7 | RMSSD During Arithmetic: Week 7 | RMSSD During Cooldown: Week 7 | |
| Oxytocin | 26.8196 | 28.5447 | 22.5526 | 21.113 | 29.7325 | 15.7941 | 16.0198 | 12.9299 | 11.3174 | 17.9728 |
| Placebo | 48.865 | 37.7607 | 20.9388 | 21.1729 | 34.5220 | 26.3299 | 28.1708 | 22.1121 | 21.2057 | 24.6587 |
"Aim 4: To evaluate the effectiveness of intranasal oxytocin on reducing stimulant craving in response the Trier Social Stress Test (TSST).~The Cocaine Craving Questionnaire (CCQ) (brief) was modified to include all stimulants and administered. The CCQ is a 10-item questionnaire, with each item ranking on a scale of 1-7. 1 indicates 'Strongly Disagree' and 7 indicates 'Strongly Agree'. Higher scores indicate higher rates of craving. The CCQ was administered at three distinct time points: before the TSST, immediately after the TSST and 20 minutes post-TSST.~The Trier Social Stress Test is a series of tasks which predictably induce stress in participants. First, physiological states are measured at baseline. Then participants are told they must prepare a 5 minute speech for a panel of researchers, which they then present. Participants are then asked verbal arithmetic questions. Finally, this is followed by a period of 5 minute rest referred to as the 'cooldown' period." (NCT03016598)
Timeframe: Visits 1 and 7, Up to 7 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre_Trier: Week 1 | Imm_Post_Trier: Week 1 | 20m_Post_Trier: Week 1 | Pre_Trier: Week 7 | Imm_Post_Trier: Week 7 | 20m_Post_Trier: Week 7 | |
| Oxytocin | 2.1667 | 2.4389 | 2.3056 | 1.7167 | 1.6833 | 1.7167 |
| Placebo | 1.82727 | 2.35 | 1.8955 | 1.42 | 1.48 | 1.67 |
Aim 7: To evaluate the effectiveness of intranasal oxytocin on reducing self-reported stress/anxiety levels in response to the TSST. The scale used to measure anxiety was the State-Trait Anxiety Inventory (STAI-6). This scale consists of 40 questions, all of which are rated on a 4-point likert scale. 1 indicates 'Almost Never' while 4 indicates 'Almost Always'. The minimum score is 0, indicating no anxiety, and maximum score is 63, indicating severe anxiety. (NCT03016598)
Timeframe: Visits 1 and 7, Up to 7 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre_Trier: Week 1 | Imm_Post_Trier: Week 1 | 20m_Post_Trier: Week 1 | Pre_Trier: Week 7 | Imm_Post_Trier: Week 7 | 20m_Post_Trier: Week 7 | |
| Oxytocin | 34.815 | 46.4815 | 36.8519 | 35.185 | 42.222 | 35.741 |
| Placebo | 32.2727 | 46.0606 | 36.97 | 29.17 | 36.5 | 31 |
Aim 2: To evaluate the effectiveness of intranasal oxytocin on improving psychosocial treatment engagement (social support) as measured by the Working Alliance Inventory, an inventory of therapeutic alliance. The Working Alliance Inventory is a 36 question inventory. Each item is scored from 1-7, minimum = 1 and maximum = 7. Minimum total score = 36 to maximum total score = 252. Higher scores represent higher satisfaction. (NCT03016598)
Timeframe: Visits 1 and 7, Up to 7 weeks
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| WAI Week 1: Self-Report | WAI Week 7: Self-Report | WAI Week 1:Therapist | WAI Week 7: Therapist | |
| Oxytocin | 3.5972 | 3.4676 | 4.088 | 4.1450 |
| Placebo | 3.8182 | 3.5208 | 3.754 | 3.7486 |
18 reviews available for 3,4-methylenedioxyamphetamine and Substance-Related Disorders
| Article | Year |
|---|---|
Altered states: the clinical effects of Ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Brain; Clinical Trials as Topic; Cognition Disorders; Hallucinogens; | 2003 |
Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place?
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Blood Coagulation Disorders; Dancing; Dantrolene; | 1993 |
Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve').
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Fever; Humans; Male; Poisoning; Substance-Rela | 1993 |
[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
Topics: 3,4-Methylenedioxyamphetamine; Animals; Designer Drugs; Humans; N-Methyl-3,4-methylenedioxyamphetami | 1996 |
[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity].
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Designer Drugs; Hallucinogens; Humans; Mental Disorde | 1998 |
[Poisoning with amphetamines and designer drugs].
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Drug Overdose; Humans; Illicit Drugs; I | 1999 |
It's a rave new world: rave culture and illicit drug use in the young.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Ephedrine; Flunitrazepam; Humans; Illicit Drugs; Ketamine | 2001 |
Use of drug discrimination in drug abuse research.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Discrimination Learning; Hallucinogens; Humans; Receptors, S | 1991 |
[MDMA ("ecstasy"): a currently used drug in Spain].
Topics: 3,4-Methylenedioxyamphetamine; Chemical Phenomena; Chemistry; Designer Drugs; Humans; N-Methyl-3,4-m | 1991 |
["Ecstasy" and "ice": the return of the amphetamines].
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Designer Drugs; Humans; N-Methyl-3,4-methylene | 1991 |
Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Humans; Lethal Dose 50; N-Methyl-3,4-methylene | 1987 |
Biological evaluation of compounds for their physical dependence potential and abuse liability. X. Drug testing programs of the Committee on Problems of Drug Dependence, Inc. (1986).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Appetite Depressants; Bridged-Ring Compounds; Chemical Pheno | 1987 |
A review of the effects of repeated administration of selected phenylethylamines.
Topics: 3,4-Methylenedioxyamphetamine; Alkaloids; Amphetamines; Animals; Central Nervous System; Central Ner | 1986 |
Preventing toxicomania and addictive behaviour in adolescence.
Topics: Adolescent; Adolescent Behavior; Animals; Behavior, Addictive; Cerebral Cortex; Disease Models, Anim | 2013 |
Is love passion an addictive disorder?
Topics: Affect; Animals; Behavior, Addictive; Brain; Dopamine; Emotions; Female; Humans; Love; Male; Neurotr | 2010 |
The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.
Topics: Animals; Behavior, Addictive; Brain; Dopamine; Humans; Love; Object Attachment; Pair Bond; Parent-Ch | 2012 |
The healing circle: resiliency in nurses.
Topics: Adaptation, Psychological; Ambulatory Care Facilities; Attitude of Health Personnel; Career Choice; | 2006 |
Date rape among adolescents and young adults.
Topics: Adolescent; Adolescent Behavior; Adult; Age Distribution; Courtship; Female; Health Knowledge, Attit | 1998 |
2 trials available for 3,4-methylenedioxyamphetamine and Substance-Related Disorders
| Article | Year |
|---|---|
Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Clinical Trials as Topic; Designer Drugs; Huma | 1990 |
Impact of Meditation on Mental Health Outcomes of Female Trauma Survivors of Interpersonal Violence With Co-Occurring Disorders: A Randomized Controlled Trial.
Topics: Adult; Behavior Therapy; Comorbidity; Emotional Adjustment; Empathy; Female; Humans; Love; Meditatio | 2017 |
127 other studies available for 3,4-methylenedioxyamphetamine and Substance-Related Disorders
| Article | Year |
|---|---|
Qualitative Screening of Amphetamine- and Ketamine-Type Abuse Drugs in Urine Employing Dual Mode Extraction Column by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Chromatography, Liquid; Ephedrine; Humans; Illicit Drugs | 2023 |
[High-risk drug use: epidemiological pattern through hair testing in the forensic context].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Amphetamine; Cannabinoids; Cocaine; Cross-Sectiona | 2019 |
A Retrospective of Prevalence of Drugs of Abuse by Hair Analysis in Shanghai using LC-MS-MS.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Central Nervous System Stimulants; China; Chroma | 2020 |
What is the drug of choice of young festivalgoers?
Topics: 3,4-Methylenedioxyamphetamine; Australia; Cocaine; Hallucinogens; Holidays; Humans; Illicit Drugs; M | 2020 |
Emergency Embolization of Artery of Adamkiewicz Pseudoaneurysm Following Methylenedioxymethamphetamine Abuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Aneurysm, False; Arteries; Computed Tomography Angiography; Em | 2019 |
Serotonin syndrome unmasking thyrotoxicosis.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Aftercare; Anti-Arrhythmia Agents; Antithyroid Agents; Carbima | 2019 |
Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Animals; Anxiety; Behavior, Animal; Body Temperatu | 2008 |
Multiple drug ingestion by ecstasy abusers in the United States.
Topics: 3,4-Methylenedioxyamphetamine; Drug Contamination; Forensic Toxicology; Hallucinogens; Humans; Illic | 2009 |
Morbidity involving the hallucinogenic designer amines MDA and 2C-I.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Chromatography, Gas; Designer Drugs; Dimethoxyphenylethylamine | 2009 |
New doves, a new legal high?
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Hallucinogens; Humans; Ireland; Substance-Related Dis | 2010 |
Estimation of community-wide drugs use via stereoselective profiling of sewage.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; England; Humans; Illicit Drugs; Methamphetamine; N-Meth | 2012 |
Amphetamines and 3,4-methylendioxymetamphetamine (MDMA): evaluation of KIMS (kinetic interaction of microparticles in solution) assay at two cut-off levels.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Amphetamines; Chromatography, High Pressure Liquid | 2004 |
Amphetamine toxicity in the emergency department.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Emergency Service, Hospital; Fatal Outcome; Fema | 2005 |
Distribution of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA) in postmortem and antemortem specimens.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Diagnosis; Female; Forensic Toxicology; Gas Chroma | 2006 |
Fatality due to the use of a designer drug MDMA (Ecstasy).
Topics: 3,4-Methylenedioxyamphetamine; Adult; Autopsy; Chromatography, Liquid; Designer Drugs; Fatal Outcome | 2007 |
The hallucinogens and the inhalants.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; DOM 2,5-Dimethoxy-4-Methylamphetamine; Dronabinol; Halluc | 1984 |
The clandestine drug laboratory situation in the United States.
Topics: 3,4-Methylenedioxyamphetamine; Acetone; Amphetamine; Drug and Narcotic Control; Humans; Illicit Drug | 1983 |
MDA--another stupefacente.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; DOM 2,5-Dimethoxy-4-Methylamphetamine; Humans; Illicit | 1982 |
Simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in human hair by gas chromatography-mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Gas Chromatography-Mass Spectrometry; Hair; Humans; Meth | 1995 |
A study of the precursors, intermediates and reaction by-products in the synthesis of 3,4-methylenedioxymethylamphetamine and its application to forensic drug analysis.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Drug and Narcotic Control; England; Forensic Medicine | 1993 |
Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Electroencephalography; Female; Humans; Male; Me | 1993 |
Cerebral infarction in association with Ecstasy abuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Cerebral Infarction; Designer Drugs; Humans; Male; N-Methyl-3, | 1993 |
A fatal overdose with 3,4-methylenedioxyamphetamine derivatives.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Cannabinoids; Cannabis; Designer Drugs; Drug Ove | 1994 |
In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Brain Chemistry; Cocaine; Designer Drugs; Female; Fen | 1994 |
Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Cross-Sectional Studies; Designer Drugs; Hallucinogens; Humans | 1994 |
A case of toxic psychosis induced by 'eve' (3,4-methylene-dioxyethylam-phetamine)
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Humans; Male; N-Methyl-3,4-methylenediox | 1993 |
Simultaneous identification of amphetamine and its derivatives in urine using HPLC-UV.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Chromatography, High Pressure Liquid; Gas Chromatography | 1993 |
'Ecstasy' induced pneumomediastinum.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Designer Drugs; Humans; Male; Mediastinal Emphysema; N-Me | 1993 |
'Ecstasy' ingestion: a case report of severe complications.
Topics: 3,4-Methylenedioxyamphetamine; Acute Kidney Injury; Adult; Amphetamine; Designer Drugs; Disseminated | 1993 |
Ecstasy and Whizz at a rave resulting in a major burn plus complications.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamine; Burns; Designer Drugs; Drug Overdose; Humans; Mal | 1993 |
Point-counterpoint. A reader writes: speed, ice, and ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adolescent Behavior; Designer Drugs; Humans; Male; N-Meth | 1993 |
'Rave' to the grave.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Humans; Male; N-Methyl-3,4-methylenedioxyamphe | 1993 |
Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Arousal; Designer Drugs; Dose-Response Relationship, Drug; Dru | 1993 |
[Epileptic insults, cerebral infarction and rhabdomyolysis as complications of amphetamine use].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Cerebral Infarction; Designer Drugs; Epilepsy, Generalize | 1996 |
QT-interval prolongation with Ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Subst | 1996 |
Pathology of deaths associated with "ecstasy" and "eve" misuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Brain; Humans; Liver; Male; Myocardium; N-Methyl-3,4-methylene | 1996 |
Use of drugs at 'raves'.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Catha; Central Nervous System Stimulants; Dancing; | 1995 |
Ecstasy and neurodegeneration. ...such as ketamine.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Drug Contamination; Ephedrine; Hallucinogens; Humans; | 1996 |
Ecstasy and neurodegeneration. gamma-Hydroxybutyrate is a new recreational drug that may lead to loss of consciousness.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Diagnosis, Differential; Humans; Seizures; Sodium Oxy | 1996 |
Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Calibration; Gas Chromatography-Mass Spectrometry; Humans; N-M | 1996 |
Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adolescent; Adult; Biopsy; Chemical and Drug Induced L | 1996 |
Ecstasy induced pneumomediastinum.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Humans; Male; Mediastinal Emphysema; Substance-Rel | 1996 |
'Raver's' haematuria.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Dancing; Exercise; Hallucinogens; Hematuria; Hum | 1996 |
Hair analysis for drug abuse. XV. Disposition of 3, 4-methylenedioxymethamphetamine (MDMA) and its related compounds into rat hair and application to hair analysis for MDMA abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Gas Chromatography-Mass Spectrometry; Hair; Ha | 1997 |
[Epidemiology of designer drug use in Spain].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Cocaine; Designer Drugs; Female; Heroin; Humans; M | 1997 |
Biochemical implications of ecstasy toxicity.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Creatine Kinase; Creatinine; Hemoglobins; Humans; Isoenzymes; | 1997 |
[Ecstasy--the way to ecstasy or despair?].
Topics: 3,4-Methylenedioxyamphetamine; Hallucinogens; Humans; Substance-Related Disorders | 1997 |
What you need to know: addiction--Ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Affect; Behavior Therapy; Humans; Mental Disorders; Patient Education | 1997 |
On acute poisoning with amphetamines.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Designer Drugs; Heroin; Humans; Narcotic Antagonists; | 1998 |
Detection of designer drugs in human hair by ion mobility spectrometry (IMS).
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Forensic Medicine; Hair; Hallucinogens; Humans; N-Met | 1998 |
The use of supercritical fluid extraction for the determination of amphetamines in hair.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Gas Chromatography-Mass Spectrometry; H | 2000 |
Deaths associated with MBDB misuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Autopsy; Cause of Death; Dancing; Female; Humans; Male; Substa | 2000 |
3,4-methylenedioxyamphetamine overdose.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Gas Chromatography-Mass Spectrometry; Humans; Ma | 1979 |
Comparison of behavior maintained by infusions of eight phenylethylamines in baboons.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Appetite Depressants; Diethylpropion; Haplorhi | 1976 |
Possible interaction between an MAOI and "ecstasy".
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Coma; Delirium; Designer Drugs; Drug Interactions; Female | 1992 |
Flashbacks following MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Hallucinations; Humans; N-Methyl-3,4-methylenedioxyam | 1992 |
Another death from Ecstacy.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Death, Sudden; Designer Drugs; Humans; Male; N-Methyl-3,4 | 1992 |
Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Combined Modality Therapy; Designer Drugs; Emotions; Female; H | 1992 |
The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Combined Modality Therapy; Designer Drugs; Humans; Mental Di | 1992 |
Hyperpyrexia induced by 3,4-methylenedioxyamphetamine ("Eve")
Topics: 3,4-Methylenedioxyamphetamine; Adult; Fever; Humans; Male; Substance-Related Disorders | 1992 |
Acute renal failure after ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Acute Kidney Injury; Adult; Designer Drugs; Humans; Male; N-Methyl-3, | 1992 |
Ecstasy and the dance of death.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Subst | 1992 |
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Female; Humans; Infant; Male; Morbidity; N-Methyl- | 1992 |
Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Arousal; Australia; Designer Drugs; Euphoria; Fema | 1992 |
An overdose of ecstasy. A role for dantrolene.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Dantrolene; Humans; Intensive Care Units; Intermittent Positiv | 1992 |
Complications of "ecstasy" misuse.
Topics: 3,4-Methylenedioxyamphetamine; Anesthesia; Emergencies; Humans; N-Methyl-3,4-methylenedioxyamphetami | 1992 |
Complications of "ecstasy" misuse.
Topics: 3,4-Methylenedioxyamphetamine; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Substance-Related Dis | 1992 |
Complications of "ecstasy" misuse.
Topics: 3,4-Methylenedioxyamphetamine; Dantrolene; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Substance | 1992 |
Misuse of ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Designe | 1992 |
Misuse of ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Designe | 1992 |
Misuse of ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adolescent; Chest Pain; Designer Drugs; Female; Humans | 1992 |
Misuse of ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Cerebrovascular Disorders; Designer Drugs; Humans; | 1992 |
Misuse of ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Designer Drugs; Humans; Male; N-Methyl-3,4-methylenedioxy | 1992 |
Drugs, music, and ideology: a social pharmacological interpretation of the Acid House Movement.
Topics: 3,4-Methylenedioxyamphetamine; Humans; Leisure Activities; Lysergic Acid Diethylamide; Mass Media; M | 1992 |
Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?
Topics: 3,4-Methylenedioxyamphetamine; Adult; Cognition Disorders; Depressive Disorder; Female; Humans; Male | 1992 |
Chronic paranoid psychosis after misuse of MDMA ("ecstasy")
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Humans; Male; N-Methyl-3,4-methylenedioxyamphe | 1991 |
Chronic paranoid psychosis after misuse of MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Female; Humans; Male; N-Methyl-3,4-methylenedi | 1991 |
Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Designer Drugs; Disseminated Intravascular Coagulation; F | 1991 |
Chronic atypical psychosis associated with MDMA ("ecstasy") abuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Chronic Disease; Humans; Male; N-Methyl-3,4-methylenedioxyamph | 1991 |
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Anxiety Disorders; Depressive Disorder; Female; Fo | 1991 |
Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Biogenic Amines; Designer Drugs; Female; Homovanillic Acid; Hu | 1990 |
[XTC, a new soft drug?].
Topics: 3,4-Methylenedioxyamphetamine; Humans; Substance-Related Disorders | 1991 |
Death associated with abuse of a "designer drug".
Topics: 3,4-Methylenedioxyamphetamine; Adult; Death, Sudden; Designer Drugs; Humans; Kentucky; Male; Substan | 1990 |
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Affect; Amphetamines; Designer Drugs; Female; Humans; Infusion | 1989 |
'Ecstasy': a human neurotoxin?
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Nervous | 1989 |
Blasted with ennui.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Humans; N-Methyl-3,4-methylenedioxyamph | 1989 |
Ecstasy abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Humans; N-Methyl-3,4-methylenedioxyamph | 1989 |
Responses to i.v. L-tryptophan in MDMA users.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Affect; Amphetamines; Designer Drugs; Female; Humans; Male; N- | 1989 |
A bit on the Wilde side: MDMA abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Drama; Famous Persons; Hallucinogens; Humans; Literatur | 1985 |
Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Body Weight; Brain; Dogs; Eating; Female; Male | 1987 |
Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; California; Humans; N-Methyl-3,4-methylenedioxyamphetam | 1987 |
New data intensify the agony over ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Haplorhini; Humans; Legislation, Drug; | 1988 |
Legal limbo for ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Humans; Legislation, Drug; N-Methyl-3,4-methyl | 1988 |
Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Behavior; Designer Drugs; Humans; Interviews as | 1988 |
'Let Others Love You Back to Health': The Role of Performance-based Support Groups for People in Recovery.
Topics: Emotions; Humans; Love; Qualitative Research; Self-Help Groups; Substance-Related Disorders | 2023 |
A Different Vision: Centering Love Not Punishment for Families Affected by Substance Use.
Topics: Child; Female; Humans; Infant; Love; Parenting; Parents; Pregnancy; Social Work; Substance-Related D | 2023 |
Romantic Attraction and Substance Use in 15-Year-Old Adolescents from Eight European Countries.
Topics: Adolescent; Alcohol Drinking; Europe; Female; Health Surveys; Humans; Love; Male; Marijuana Smoking; | 2019 |
When People You Love Are The Unintended Consequences Of Opioid Policy.
Topics: Analgesics, Opioid; Chronic Disease; Chronic Pain; Female; Health Policy; Humans; Kidney Failure, Ch | 2019 |
Disruption of Transitions in High-Risk Substance Use from Adolescence to Young Adulthood: School, Employment, and Romantic Relationship Factors.
Topics: Adolescent; Adolescent Behavior; Adult; Child; Employment; Female; Humans; Interpersonal Relations; | 2020 |
The role of Ecstasy (MDMA) in managing intimacy and conflict in stable relationships.
Topics: Adolescent; Adult; Conflict, Psychological; Female; Humans; Interpersonal Relations; Interviews as T | 2018 |
The core of love when caring for patients suffering from addiction.
Topics: Adult; Empathy; Female; Hermeneutics; Humans; Love; Middle Aged; Norway; Nurse-Patient Relations; Nu | 2015 |
Can we bottle psychosocial treatments for addiction? The role of oxytocin.
Topics: Animals; Humans; Love; Oxytocin; Self-Help Groups; Social Behavior; Substance-Related Disorders | 2014 |
Understanding the Life Histories of Pregnant-Involved Young Aboriginal Women With Substance Use Experiences in Three Canadian Cities.
Topics: Adult; Adult Survivors of Child Abuse; Alcoholism; Canada; Female; Humans; Indians, North American; | 2017 |
(Ad)ministering love: providing family foster care to infants with prenatal substance exposure.
Topics: Disabled Children; Family; Female; Foster Home Care; Humans; Infant; Love; Pregnancy; Prenatal Expos | 2008 |
Multi-system influences on adolescent risky sexual behavior.
Topics: Adolescent; Adolescent Behavior; Attitude to Health; Family; Female; Health Knowledge, Attitudes, Pr | 2010 |
Drug addiction, love, and the higher power.
Topics: Humans; Love; Religion and Psychology; Substance-Related Disorders | 2011 |
Triggers of mania and depression in young adults with bipolar disorder.
Topics: Adolescent; Adult; Bipolar Disorder; Creativity; Depression; Female; Holidays; Humans; Life Change E | 2012 |
Dynamical models of happiness.
Topics: Adaptation, Psychological; Antidepressive Agents; Bipolar Disorder; Dose-Response Relationship, Drug | 2005 |
Dating, sex, and substance use as correlates of adolescents' subjective experience of age.
Topics: Adolescent; Adult; Age Factors; Attitude; Female; Humans; Love; Male; Sexual Behavior; Substance-Rel | 2007 |
The elusive romance of motherhood:drugs, gender, and reproduction in inner-city distressed households.
Topics: Adult; Attitude; Black or African American; Decision Making; Family; Female; Humans; Love; Maternal | 2006 |
Observing differences between healthy and unhealthy adolescent romantic relationships: substance abuse and interpersonal process.
Topics: Adolescent; Alcoholism; Communication; Conflict, Psychological; Courtship; Dominance-Subordination; | 2008 |
Motivation for self-administration of LSD.
Topics: Anxiety; Behavior; Depression; Humans; Love; Lysergic Acid Diethylamide; Motivation; Personality; Su | 1967 |
[Witches' ointments and love-potions: a contribution to the cultural history of nightshades].
Topics: Alkaloids; Anesthesia; History, Ancient; History, Medieval; History, Modern 1601-; Humans; Love; Occ | 1998 |
Transference phenomena in the treatment of addictive illness: love and hate in methadone maintence.
Topics: Countertransference; Defense Mechanisms; Denial, Psychological; Hate; Humans; Love; Methadone; Psych | 1977 |
A factor-analytic examination of sexual behaviors and attitudes and marihuana usage.
Topics: Adult; Age Factors; Attitude; Authoritarianism; Cannabis; Contraception; Erotica; Extramarital Relat | 1975 |
[Psychological concerns in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Attitude to Death; Humans; Love; Substance-Related Disorders | 1989 |
Violent crime, sociopathy and love deprivation among adolescent delinquents.
Topics: Adolescent; Antisocial Personality Disorder; Crime; Humans; Juvenile Delinquency; Love; Male; Psycho | 1987 |
Differences among youthful users and nonusers of drugs based on their perceptions of parental behavior.
Topics: Adolescent; Amphetamine; Authoritarianism; Barbiturates; Cannabis; Ethnicity; Female; Hostility; Hum | 1974 |
Family therapy and drug abuse.
Topics: Adolescent; Attitude; Family Therapy; Humans; Love; Parent-Child Relations; Self Concept; Sexual Beh | 1972 |
The urban commune: fact or fad, promise or pipedream?
Topics: Cooperative Behavior; Decision Making; Female; Group Processes; Humans; Leadership; Life Style; Love | 1973 |
Self and ideal self-concept in a drug-using subculture.
Topics: Adolescent; Adult; Anger; Attitude; Female; Group Processes; Hostility; Humans; Interpersonal Relati | 1971 |
Patient values on an adolescent drug unit.
Topics: Adolescent; Female; Hospitals, Psychiatric; Humans; Income; Love; Male; Morals; Occupations; Ownersh | 1970 |
[Use of psychotropic drugs by young people].
Topics: Adolescent; Adult; Humans; Love; Netherlands; Social Conditions; Social Conformity; Substance-Relate | 1970 |
Problems in understanding adolescents.
Topics: Achievement; Adolescent; Anxiety; Communication; Defense Mechanisms; Family Practice; Fantasy; Femal | 1968 |
Flight from violence: hippies and the green rebellion.
Topics: Aggression; Cannabis; Defense Mechanisms; Hostility; Humans; Love; Lysergic Acid Diethylamide; Philo | 1968 |
The psychedelics: love or hostility potion?
Topics: Adult; Aggression; Female; Hallucinogens; Hostility; Humans; Love; Male; Substance-Related Disorders | 1969 |
Love- and hate-addiction in delinquent male adolescents.
Topics: Adolescent; Aggression; Alcoholism; Defense Mechanisms; Hate; Humans; Juvenile Delinquency; Love; Ma | 1965 |